Study Condition(s): Liver Cancer
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Study Alias: JBAK
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria